Evidence map›Paper›PMID 41270073›Full record

ArticlePloS one2025

One step synthesis of ultrafine PHF@AuNPs nanocomposite and its application in NIR triggered photodynamic therapy.

Wenhao Li, Bohao Ruan, Xinyi Chen, Feng Zhou, Xiaoyi Sun, Yuanyuan Lv

RetractedAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Current Perspectives on Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Wenhao LiDepartment of Pharmacy, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
Bohao RuanDepartment of Pharmacy, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
Xinyi ChenDepartment of Pharmacy, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
Feng ZhouPersonalized Prescribing Inc., Richmond Hill, Ontario, Canada.
Xiaoyi SunDepartment of Pharmacy, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-6864-1715
Yuanyuan LvDepartment of Pharmacy, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a rapid advancing treatment for cancer therapy. The main challenges in PDT include poor absorption in the "tissue optical window" and aggregation tendency of photosensitizers (PS) such as fullerene in aqueous solutions. Herein, we developed a potent nano PS: fullerene hybrid gold nanoparticles (AuNPs) composites which were ultrafine and well-dispersed with a absorption in near infrared (NIR) region. The composites could be facilely prepared by mixing the reducing and capping agent polyhydroxyl fullerene (2 mg/mL) with HAuCl4 (2.425 mM) at equal volume for 2 h. The obtained composites were negatively charged (-26.3 mv) with the particle size of 14.3 nm. A thin layer of fullerene (~1.6 nm) was coated on the AuNPs core. AuNPs in the composites acted as the light collector, absorbing the NIR light and transferring electrons or energy to the fullerene. Consequently, the composites can be efficiently internalized by tumor cells and activated to produce reactive oxygen species (ROS) intracellularly by 808 nm laser. Enhanced PDT efficacy was observed with the IC50 value (50 μg/mL) of the light-activated cytotoxicity and a negligible dark toxicity in vitro. This research provides new insights and methods for developing NIR light-triggered fullerene@AuNPs in PDT.

Indexed as

FullerenesGoldMetal NanoparticlesNanocompositesPhotochemotherapyPhotosensitizing AgentsCell Line, TumorHumansInfrared RaysReactive Oxygen SpeciesFullerenesGoldPhotosensitizing AgentsReactive Oxygen Species

Identifiers

PMID41270073
PMCPMC12637887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.